Dapagliflozin attenuates ferroptosis in diabetic nephropathy through activation of the Nrf2/HO-1 signaling pathway
Hanshuang Liu, Xiaoxiao Zhang, Yubing Cui, Shengxi Xiong, Linjuan Huang, Min Li, Chen Shao, Xiaolei Hu · 2026
Read Dapagliflozin attenuates ferroptosis in diabetic nephropathy through activation of the Nrf2/HO-1 signaling pathway by Hanshuang Liu, Xiaoxiao Zhang, Yubing Cui, Shengxi Xiong, Linjuan Huang, Min Li, Chen Shao, Xiaolei Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13155870.txt.
Description
Hanshuang Liu and seven co-authors published a 2026 study on a diabetes drug that may protect kidneys from a form of cell death. In diabetic nephropathy, kidney tubule damage drives the disease forward. Ferroptosis, a cell death route that depends on iron, has been tied to that damage.
The drug, dapagliflozin, is a blood sugar drug already known to slow kidney decline. The team tested it in diabetic mice and in human kidney tubule cells grown in high sugar. The drug eased tissue damage seen under the microscope. It raised three protective proteins tied to ferroptosis defense and lowered a protein that pulls iron into cells. These shifts ran through a known defense pathway in the cell, suggesting the drug's benefit is partly anti ferroptotic.
Catalog record
| CREATOR | Hanshuang Liu, Xiaoxiao Zhang, Yubing Cui, Shengxi Xiong, Linjuan Huang, Min Li, Chen Shao, Xiaolei Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |